Skip to main content
Evidence Snapshot

Squalene synthase

CHEMBL3338 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3338
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Squalene synthase as ChEMBL target CHEMBL3338, mapped to UniProt P37268. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Squalene synthase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3338
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P37268
Squalene synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Squalene synthase matters

As of 2026-09-13

Squalene synthase is reviewed as Squalene synthase (UniProt P37268); Squalene synthase shows late clinical disease relevance led by Disorder of lipid metabolism. 3 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 315 compounds, and 40 assays, with lead potency reaching pChEMBL 9.7.

Disease context
Disorder of lipid metabolism

Squalene synthase shows late clinical disease relevance led by Disorder of lipid metabolism. 3 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include LAPAQUISTAT ACETATE.

Start review with Disorder of lipid metabolism because it currently carries late clinical support. Linked drugs include LAPAQUISTAT ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 315 compounds, and 40 assays for this target. The dominant activity type is IC50. CHEMBL507677 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL507677 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 9.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Squalene synthase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P37268, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Disorder of lipid metabolism is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

315
Total Compounds
40
Total Assays
1
Approved Drugs
IC50: 296.0, KI: 20.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL507677
 9.7 IC50 —
No preferred name
CHEMBL40991
 9.6 IC50 —
No preferred name
CHEMBL335394
 9.6 IC50 —
No preferred name
CHEMBL436588
 9.5 IC50 —
No preferred name
CHEMBL505374
 9.5 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3338